Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

GVAX

Vaccine · Immune activation · developed by Cell Genesys

Phase 1/2 Most advanced trial
1 Registered trials

What is GVAX?

GVAX is a cell-based vaccine administered as intradermal injections. It is being studied in pancreatic cancer as part of a treatment regimen that includes surgery and chemotherapy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine
Mechanism
Immune activation
Therapy area
Oncology
Developer
Cell Genesys
In trials of
AGEN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06782932 Phase 1/2 Pancreatic Cancer Recruiting AGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic Cancer

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.